GlassScriptPhysician profile
Cameron Zenger
NPI 1336729797
$1,256.00
in general payments reported to CMS, 2019-2025
14 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.01 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $250.15 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $176.59 | 2025 | Entyvio |
| Abbvie INC. | $172.47 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.93 | 2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $121.11 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $96.99 | 2025 | Dupixent |
| Genzyme Corporation | $84.36 | 2025 | |
| Lilly USA, LLC | $33.26 | 2025 | Omvoh |
| Celltrion USA INC. | $31.04 | 2025 | Vegzelma |
| Azurity Pharmaceuticals, INC. | $29.58 | 2025 | Triptodur |
| Intercept Pharmaceuticals, INC. | $28.38 | 2025 | |
| Evoke Pharma, INC. | $23.56 | 2025 | |
| Ferring Pharmaceuticals INC. | $22.00 | 2025 | Rebyota |
| Pfizer INC. | $14.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Zenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.